Guide to the Shifting State of Real-World Evidence

A paradigm shift has occurred in the field of real-world evidence (RWE) and health economics and outcomes research (HEOR) in recent years. Navigating the new landscape requires keeping up with the shifting priorities of international health technology assessment (HTA) bodies, making careful partnerships, and understanding the various sources of RWE and real-world data (RWD) that are driving decision-making.

According to Lumanity, “Many more types of data becoming available sounds like a total win, but just because there are more data doesn’t mean all sources are suitable – you have to be able to evaluate each source for quality, completeness, relevancy and, most importantly, appropriateness. Does the data cover the right population for the treatment, and is it an accurate representation of the cohort? Some companies offering data and analysis also over-promise on what can actually be delivered using RWD today – it has lots to offer but is not a magic cure-all for all uncertainties around a new healthcare product.”

To read more, click here.

(Source: BioPharmaDive, November 14^th, 2022)